Jivi, antihemophilic factor (recombinant), PEGylated-aucl, is a recombinant DNA-derived, Factor VIII concentrate indicated for use in previously treated adults and adolescents (12 years of age …
Show more
See More
Jivi antihemophilic factor (recombinant), PEGylated-aucl, is a recombinant DNA-derived, Factor VIII concentrate indicated for use in previously treated adults and adolescents (12 years of age …
Show more
See More
Jivi [antihemophilic factor (recombinant), PEGylated-aucl] is a sterile, nonpyrogenic, preservative-free, white to slightly yellow lyophilized powder for reconstitution with sterile Water for Injection (sWFI) as diluent for intravenous (IV) administration. The product is supplied in single-use vials...
Gray: 3000 IU with 2.5 mL SWFI
Red: 1000 IU with 2.5 mL SWFI
Green: 500 IU with 2.5 mL SWFI
Yellow: 2000 IU with 2.5 mL SWFI
Show more
See More
Jivi is used to treat and control bleeding in previously treated adults and adolescents (12 years of age and older) with hemophilia A. Your healthcare provider may also give you Jivi when you …
Show more
See More
Overview Jivi is a medicine used to treat and prevent bleeding in patients with haemophilia A, an inherited bleeding disorder caused by lack of a clotting protein called factor …
Show more
See More
Sep 07, 2018 . Jivi is formulated with the following excipients: 59 mg glycine, 27 mg sucrose, 8.4 mg histidine, 4.7 mg sodium chloride, 0.7 mg calcium chloride, and 0.216 mg polysorbate 80. …
Show more
See More
Jivi antihemophilic factor (recombinant), PEGylated-aucl, is a recombinant DNA-derived, Factor VIII concentrate indicated for use in previously treated adults and adolescents (12 years of age …
Show more
See More
JEVI has been manufacturing heating elements since 1942, and over the past few years, we have been manufacturing around 150,000 heating elements a year. Heating elements are …
Show more
See More
Use Jivi (antihemophilic factor (recombinant [pegylated-aucl])) as ordered by your doctor. Read all information given to you. Follow all instructions closely. It is given as a shot …
Show more
See More
Lääkeinfo.fi - Suomessa myytävien lääkevalmisteiden pakkausselosteet. Jivi injektiokuiva-aine ja liuotin, liuosta varten 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU
Show more
See More
Find everything you need to know about Jivi, including what it is used for, warnings, reviews, side effects, and interactions. Learn more about Jivi at EverydayHealth.com.
Show more
See More
Alphanate Prescribing Information Patient
Jivi
Show more
See More
The specific activity of Jivi is approximately 10,000 IU/mg protein. The active protein (or starting molecule), prior to conjugation is a recombinant B-domain deleted human coagulation Factor VIII (BDD-rFVIII) produced by recombinant DNA technology in Baby Hamster Kidney (BHK) cells.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Jivi antihemophilic factor (recombinant), PEGylated-aucl, is a recombinant DNA-derived, Factor VIII concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with hemophilia A (congenital Factor VIII deficiency) for:
Jivi [antihemophilic factor (recombinant), PEGylated-aucl] is a sterile, nonpyrogenic, preservative-free, white to slightly yellow lyophilized powder for reconstitution with sterile Water for Injection (sWFI) as diluent for intravenous (IV) administration.
Jivi is available as a white to slightly yellow lyophilized powder in single-use glass vials containing nominally 500, 1000, 2000, or 3000 IU of Factor VIII potency per vial. Each vial of Jivi is labeled with actual Factor VIII potency expressed in IU determined using a chromogenic substrate assay.
Jivi is an injectable medicine used to replace clotting factor (Factor VIII or antihemophilic factor) that is missing in people with hemophilia A. Jivi is used to treat and control bleeding in previously treated adults and adolescents (12 years of age and older) with hemophilia A.
The European Medicines Agency decided that Jivi’s benefits are greater than its risks and it can be authorised for use in the EU. Studies show that Jivi is effective at preventing and treating bleeding episodes in patients with haemophilia A and its safety is comparable to that of other factor VIII products.
Since this could potentially cause problems especially in children below 12 years of age, Jivi is only approved for use in adults and children from 12 years of age. What measures are being taken to ensure the safe and effective use of Jivi?
Studies show that Jivi is effective at preventing and treating bleeding episodes in patients with haemophilia A and its safety is comparable to that of other factor VIII products.